الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Introduction:- Helicobacter Pylori (HP) infection is considered a risk factor of GIT diseases e.g., gastric, duodenal ulcers, and gastric carcinomas. It is transmitted through Feco/oral route and can be diagnosed by many methods e.g.; Stool Antigen Test (SAT). Metabolic syndrome (MET S) is considered a circle of metabolic derangements that can cause some complications as ischemic changes and heart diseases. It may also cause Nonalcoholic fatty liver disease (NAFLD), resulting in inflammation and the potential for cirrhosis and HCC. Patients and methods: - A Case-Control Study with 2 Groups of patients of MET S either with or without NAFLD and age-matched controls (100 individuals in each group). Full clinical examination and lab investigations were done + SAT to all study patients to evaluate the possible correlation between HP Infection and MET S with the coexistence of NAFLD, declaring if HP Infection may have a role in NAFLD occurrence and progression especially in the presence of other metabolic abnormalities of MET S. Results: The Study found HP Infection is more frequent in MET S with NAFLD patients (73%) than in MET S without NAFLD (47%) with (P value<0.001) emphasizing that HP Infection increases the risk of NAFLD development in patients with MET S. The study also found that HP Infection is associated with an increased degree of fibrosis significantly (P-value < 0.001) with progression to marked fibrosis which may complicate with NASH with the overall predictive value of 75% especially in patients with Dysglycemia. Conclusion:* Our findings show a circle of metabolic abnormalities that seems to be attributed to HP Infection in MET S patients increases the risk of NAFLD and progression to marked fibrosis especially with coexistent Dysglycemia, Dyslipidemia, and Upper Body Obesity. * HP Infection should be kept in mind in patients with MET S. *Diagnosis and early eradication of it will help in decreasing metabolic disturbances, the possibility of NAFLD, and protect against marked fibrosis progression.